Vagal Blocking Improves Glycemic Control and Elevated Blood Pressure in Obese Subjects with Type 2 Diabetes Mellitus

Table 1

% EWL and change in glycemic parameters (mg/dL) and blood pressure (mmHg) from baseline over 12 months.

Parameter	Time following device activation—change from baseline						𝑃 value
	Baseline	1 week	4 weeks	12 weeks	6 months	12 months
EWL %, 𝑛=28	0	9±1	14±2	21±3	24±4	25±4	<.0001
HbA1c (%), 𝑛=28	7.8±0.2	−0.3±0.1	−0.7±0.1	−0.9±0.2	−0.9±0.2	−1.0±0.2	.02
FPG (mg/dL), 𝑛=28	151±7	−21±6	−19±7	−27±8	−29±8	−28±8	.01
MAP, all subjects (mmHg), 𝑛=28	95±2	−4±2	−5±2	−5±2	−8±2	−3±2	.04^#
SBP, all subjects (mmHg), 𝑛=28	125±2	−3±3	−7±3	−6±3	−8±3	−4±3	.04^∧
DBP, all subjects (mmHg), 𝑛=28	80±2	−5±2	−4±2	−4±2	−8±2	−2±2	.04^&
MAP elevated (mmHg), 𝑛=15	100±2	−7±3	−9±3	−9±2	−13±2	−8±3	.04
SBP elevated (mmHg), 𝑛=8	140±4	−10±9	−12±10	−13±5	−16±8	−12±9	.03^∗
DBP elevated (mmHg), 𝑛=12	88±2	−10±2	−10±3	−9±1	−14±2	−10±3	.009

#At 1, 4, and 12 weeks and 6 months; ∧at 4 weeks, 12 weeks and 6 months; &at 1 week, 12 weeks and 6 months; *at 12 weeks.
FPG: fasting plasma glucose, MAP: mean arterial pressure, SBP: systolic blood pressure, and DBP: diastolic blood pressure.